Stem-cell derived exosome vesicle products
Identification
- Name
- Stem-cell derived exosome vesicle products
- Accession Number
- DB15743
- Description
Mesenchymal stem cells (MSCs) exert their therapeutic effects through multiple modalities, including paracrine factors such as exosomes. Exosomes are nanometer-sized, membrane-bound vesicles secreted for the purpose of cell-cell communication. Once secreted into extracellular fluid, exosomes are taken up by their target cells or carried to distant target sites. Various bioactive molecules (including lipids, proteins, mRNAs, and tRNAs) are used to enrich exosomes. While many contain a conserved set of proteins, they also carry unique tissue type-specific proteins. These products originate from multiple cellular types, including immunocytes, tumor cells, and mesenchymal stem cells (MSCs) originating from various tissues.
Exosomes from MSCs carry cytokines and growth factors, like TGFB1, IL-6, IL-10, and hepatocyte growth factor (HGF); all are shown to be immunomodulatory. These exosomes can also consist of VEGF and matrix metalloproteinase-9 (MMP-9) which aid in angiogenesis and tissue repair.
- Type
- Biotech
- Groups
- Investigational
- Biologic Classification
- Cell transplant therapies
Other cell transplant therapies - Synonyms
- DB-001
- Stem-cell derived exosome vesicles
- Stem-cell derived extracellular vesicle products
- Stem-cell derived extracellular vesicles
- External IDs
- Stem-cell derived exosome vesicle products
Pharmacology
- Indication
- Not Available
- Contraindications & Blackbox Warnings
Learn about our commercial Contraindications & Blackbox Warnings data.
Learn More- Pharmacodynamics
- Not Available
- Mechanism of action
Exosomes are a novel cell-therapy currently investigated for the treatment of liver, kidney, cardiovascular, and neurological disease. They are messengers in intercellular communication through their ability to secrete bioactive lipids, proteins, and RNAs to target sites. As they can carry unique proteins and cytokines, exosomes are involved in both physiological and pathological processes. Therapeutically, MSC-derived exosomes can restore tissue homeostasis, and enable tissue recovery, repair, and regeneration.
- Absorption
- Not Available
- Volume of distribution
- Not Available
- Protein binding
- Not Available
- Metabolism
- Not Available
- Route of elimination
- Not Available
- Half-life
- Not Available
- Clearance
- Not Available
- Adverse Effects
Learn about our commercial Adverse Effects data.
Learn More- Toxicity
- Not Available
- Affected organisms
- Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.Not Available
- Food Interactions
- Not Available
Categories
- Drug Categories
- Not Available
- Classification
- Not classified
Chemical Identifiers
- UNII
- Not Available
- CAS number
- Not Available
References
- General References
- Saha P, Sharma S, Korutla L, Datla SR, Shoja-Taheri F, Mishra R, Bigham GE, Sarkar M, Morales D, Bittle G, Gunasekaran M, Ambastha C, Arfat MY, Li D, Habertheuer A, Hu R, Platt MO, Yang P, Davis ME, Vallabhajosyula P, Kaushal S: Circulating exosomes derived from transplanted progenitor cells aid the functional recovery of ischemic myocardium. Sci Transl Med. 2019 May 22;11(493). pii: 11/493/eaau1168. doi: 10.1126/scitranslmed.aau1168. [PubMed:31118291]
- Lai RC, Yeo RW, Lim SK: Mesenchymal stem cell exosomes. Semin Cell Dev Biol. 2015 Apr;40:82-8. doi: 10.1016/j.semcdb.2015.03.001. Epub 2015 Mar 9. [PubMed:25765629]
- Yin K, Wang S, Zhao RC: Exosomes from mesenchymal stem/stromal cells: a new therapeutic paradigm. Biomark Res. 2019 Apr 4;7:8. doi: 10.1186/s40364-019-0159-x. eCollection 2019. [PubMed:30992990]
- External Links
- Not Available
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 2 Not Yet Recruiting Treatment Acute Respiratory Distress Syndrome (ARDS) / Coronavirus Disease 2019 (COVID‑19) / Viral Pneumonia 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
- Not Available
- Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
Drug created on August 11, 2020 15:13 / Updated on September 19, 2020 20:19